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Abstract	
Aim:	The epidemiology of Acute Kidney Injury (AKI) diagnosed in the Emergency Department 
(ED) is poorly described. This study describes the incidence, demographics and outcomes of 
patients diagnosed with AKI in the ED (ED-AKI). 
Methods:	A prospective cohort study was completed in a University Teaching Hospital, (UK) 
between April and August 2016. In total 20,421 adult patients attended the ED and had a 
serum creatinine measurement. The incident ED-AKI patient episodes were compared to a 
randomly selected cohort of non-AKI ED patients.  
Results: 572 patients had confirmed eAlert ED-AKI (548 incident cases), give an incidence of 
2.8% (of all ED attendances). ED-AKI was associated with a 24.4% in patient mortality (non-
AKI 3.2%, p<0.001) of which 22.3% of deaths occurred within 24-hours and 58% within 7-
days. Progression of the admission AKI stage to a higher AKI stage was associated with a 
38.8% mortality compared to a 21.4% mortality in those who did not progress (p<0.001). In 
multivariate analysis ED-AKI was an independent risk for mortality (HR, 6.293; 95% CI, 1.887 
to 20.790, p=0.003). For those discharged from hospital 20.4% of ED-AKI patients re-attend 
for acute assessment within 30-days post discharge (non-AKI 7.6%, p<0.001). At 90-days post 
discharge 10.0% of ED-AKI patients died (non-AKI 1.4%, p<0.001). 12-months post discharge 
17.8% of ED-AKI patients developed CKD progression or de-novo CKD (non-AKI 6.0%).   
Conclusion: ED-AKI is an independent predictor of death. Mortality is predominantly in the 
early stages of hospital admission, but for those who survive to discharge have significant 
long-term morbidity and mortality.   
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Introduction 
Acute Kidney Injury (AKI) is a common medical emergency, complicating 6-18% of all 
hospital admissions
(1-3)
. There are however, significant variations in the disease phenotype. 
For example markedly differing mortality has been reported when diagnosed in the 
community (CA-AKI, 19-26%)
(1, 4-6)
, hospital (HA-AKI, 30-43-%)
(1, 4, 6, 7)
 and within the Intensive 
Care Unit (ICU-AKI, 22-53%)
(8-12)
. In surviving patients long term consequences are well 
recognised as survivors are at increased risk of de-novo/progressive Chronic Kidney Disease 
(CKD)
(13)
, End Stage Renal Disease (ESRD)
(14)
 and early death
(15)
. 
AKI diagnosed in hospital forms the corner stone of a number of in hospital mortality 
prediction models
(16-18)
. Furthermore, AKI is a major risk factor for long-term mortality
(16)
 and 
impaired neurological outcomes
(19)
 following cardio-pulmonary resuscitation. It is unknown if 
a window of opportunity exists were early identification and aggressive resuscitation can 
circumvent acute mortality and reduce long-term morbidity. 
Our group has previously reported that at a national level CA-AKI contributes to 50% 
of all AKI events of which half alerted in the Emergency Department, (ED)
(4, 5)
. Despite an 
annual ED attendance of 23.4 million patients in NHS England 
(20)
, very little is known 
regarding the impact of AKI at the hospital front door, specifically in the ED. To date there 
have been only two publications investigating AKI in the ED (ED-AKI). Of these, the first 
described the demographics and risk factors of a small ED-AKI cohort in which AKI was 
diagnosed on the basis of change in serum creatinine (sCr)
(21)
, and the second involved a 
larger cohort in which AKI was retrospectively diagnosed from administrative data
(22)
.  
ED-AKI represents an important cohort with a significant paucity of data. To inform 
further research and guide clinical endpoints a detailed description of ED-AKI is required. 
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In this observational study we compared epidemiology data, risk factors and 
outcome, of the largest cohort reported to date of adult patients admitted with AKI 
diagnosed in the ED and compared these to a cohort of randomly selected patients admitted 
to ED without AKI (non-AKI). 
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Methods  
Setting  
This retrospective, single-centre study was conducted over a 17-month period (1
st
 
April 2016 to 31
st
 August 2017) in a University Hospital, Tertiary Referral, Major Trauma and 
Emergency Care Centre in South Wales (UK) (1080 general beds, 54 ICU beds), serving a 
population of 445,000. ED attendance was defined as those patients who attended the ED 
directly and those who were referred to the Acute Medical Assessment Unit and the Acute 
Surgical Assessment Unit directly from primary care.  
 
Electronic Reporting System 
The previously described (and validated) Welsh electronic AKI reporting system 
(InterSystems TrakCare Lab) was used to identify patients with sCr rises consistent with a 
diagnosis of AKI
(4, 23)
. The system processes data in real time, automatically comparing sCr 
levels against historic data (sCr within 365 days) to generate alerts on the basis of the Kidney 
Disease Improving Global Outcomes (KDIGO) criteria
(24)
.  
 
Data Collection 
All adult patients (≥18 years of age) who attended the ED and had a sCr test between the 1
st
 
April and 31
st
 August 2016 were eligible for inclusion. Patients were grouped to either ED-AKI 
or non-AKI dependent upon the generation of an AKI e-alert at ED presentation. Any patient 
generating an e-alert but at manual data analysis were identified as received a renal 
transplant, undergoing renal replacement therapy, those who due to incorrect lab-coding 
had not generated an alert in the ED and any patient self-discharging prior to assessment by 
a doctor were excluded from the analysis. To inform the true eAlert ED-AKI incidence, all 
 7 
patients who were admitted or discharged (the total number of renal function tests) were 
compared to the total number of true positive eAlert ED-AKI episodes to generate the 
incidence demominator.  
 A non-AKI control cohort was generated from the incident patients attending the ED 
with no AKI e-alert by random selection using the random number generating function, 
Microsoft® Excel® (Ver: 16.11.1), followed by number ordering and selection of the first 600 
cases
(25)
.  
Following cohort selection all electronic patient records were manually searched by a 
single nephrologist and demographic, clinical and laboratory data was collated. Pre-existing 
baseline sCr was defined following review of all historic sCr data. For those with no historic 
data, admission and post-discharge sCr was reviewed and extrapolated to infer pre-existing 
baseline. Similarly, all sCr results within 12-months post discharge were trended to describe 
new baseline. AKI and CKD were defined by KDIGO AKI
(26)
 and CKD
(27)
 criteria. eGFR was 
calculated using the Modification of Diet in Renal Disease Study (MDRD) equation
(28)
. Pre-
existing CKD was classified as stage 3A-5 only. All sCr results at presentation to the ED from 
each cohort was compared to baseline to validate the e-alerts. Recovery from AKI was 
defined as achievement of sCr no longer in keeping with AKI. AKI progression was defined as 
a peak AKI stage higher than the stage associated with the incident e-alert or for stage 3 
alerts an increase ≥50% from the sCr generating the alert
(23)
. 
Hospital admission was defined either as those patients who attended the ED but 
died within 24 hours of admission to hospital or those who attended the ED but were 
admitted for >24 hours. Recent admission and re-admission within 30-days of incident case 
was defined as presentation to the ED for acute care or any unscheduled acute hospital 
admission. Discharge was defined as those who were discharged within 24-hours of ED 
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presentation and those who were discharged following hospital admission.  All discharged 
patients were followed up for 12 months. 
 
Statistics 
Statistical analysis was carried out using SPSS software, version 23 (IBM SPSS, Chicago, 
IL). Normally distributed data was analysed using t-test. Categorical data were compared 
using chi-squared test. Data which is non-normally distributed were analysed using Mann-
Whitney U test and Kruskal-Wallis test. Continuous variables are described as mean ±SD or 
median and interquartile range (IQR). Multivariate Cox proportional hazard modelling was 
used to determine the significance of variables on inpatient mortality. Kaplan-Meier survival 
analysis was performed to assess 90-day mortality. P values ≤0.05 were considered 
statistically significant. 
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Results 
Patient Cohort 
During the five-month cohort identification there were 20,421 ED adult patient 
contacts who had a sCr test performed. In total 648 ED-AKI e-alerts occurred. Following 
review of historical sCr results and application of exclusion criteria 572 AKI cases were 
confirmed, giving an overall ED-AKI incidence of 2.8%. Of the 572 ED-AKI eAlerts, 548 incident 
cases were identified and entered into analysis (n=24 repeat admissions with ongoing AKI i.e 
this is the same patients with a second (or more) episode? – the wording needs a little more 
clarrity). In total 600 non-AKI cases were randomly selected from 17,145 incident non-AKI 
cases. Of these 571 were selected for analysis following application of the exclusion criteria, 
figure 1.  
 
Demographic Data 
On average ED-AKI patients were 15-years older (70.3 versus 54.7 p<0.001), a greater 
proportion were male (54.9% versus 46.2%, p=0.004), and nursing or residential home 
residents at the time of admission (19.5% versus 6.5%, p<0.001) compared to the non-AKI 
cohort. A greater proportion of the ED-AKI cohort had pre-existing CKD (27.6% versus 7.9% 
non-AKI, p<0.001) and a greater proportion of all co-morbid conditions investigated except 
for Connective Tissue disease/Vasculitis which no difference was demonstrated, table 1. 
 
ED Contact Data and Investigations 
 At presentation, a greater proportion of patients in the ED-AKI group had Stage 1 AKI 
(68.8%), than stage 2 (20.4%) or stage 3 (10.8%). A larger proportion of patients with ED-AKI 
were admitted to hospital, 83.8% (n=459) compared to 32.9% (n=188, p<0.001) of the 
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control non-AKI ED patients. ED-AKI was most commonly associated with a discharge 
diagnosis of sepsis, co-existing in 34.1% of cases, table 2. 
 A greater proportion of patients presenting with ED-AKI had attended the ED in the 
preceding 30-days compared to the non-AKI group (18.6% versus 13.3%, p=0.018). At 
presentation to the ED, ED-AKI patients were more likely to demonstrate derangement of 
liver function compared to the non-AKI group; Alanine transaminase (58.2 versus 34.9 U/L, 
p<0.001), Bilirubin (22.0 versus 12.6 umol/L, p<0.001) and lower albumin (31.1 versus 36.1 
g/L, p<0.001). The ED-AKI group also had greater increases in inflammatory markers when 
compared to the non-AKI group, CRP (107.3 versus 29.9 mg/L, p<0.001) and WBC (12.8 
versus 9.7 x 10 
9
/L, p<0.001). 
 
Inpatient Outcomes 
 In total 647 patients were admitted to hospital from the ED (across both ED-AKI and 
non-AKI cohorts). Of the ED-AKI cohort 83.8% were admitted compared to 32.9% of the non-
AKI cohort (p<0.001). Figure 2 (i) is a detailed flow diagram of the patient journey from 
admission to discharge or death. Of those admitted to hospital with ED-AKI 2.2% (n=10) 
required inpatient renal replacement therapy (RRT) compared to none in the non-AKI cohort.  
 Overall the inpatient ED-AKI mortality was 24.4% (n=112), compared to 3.2% (n=6) in 
the non-AKI cohort (p<0.001). ED-AKI mortality was associated with peak AKI stage reached 
during admission, stage 1-3 mortality; 17.2%, 27.1% and 40.7% respectively. For those in the 
admission ED-AKI cohort, 80 progressed to a higher AKI stage during their admission; AKI 
progression occurred in 53 stage one patients (66.2%), 24 AKI stage two (30%) and 3 AKI 
stage three patients (3.8%). Mortality in the ED-AKI progression group was 38.8%, compared 
to 21.4% in the non-progresses (p<0.001), Figure 2 (ii). Of those admitted with ED-AKI, 9.8% 
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(n=45) required Intensive-Care-Unit (ICU) admission during their inpatient stay. Of the total 
number of ICU admissions, 60% (n=27) occurred in the first 24-hours of presentation to 
hospital. No patient in the non-AKI cohort was admitted to ICU (table 3). In-patient mortality 
in those admitted with ED-AKI to the ICU was 31.1%. 
22.3% of all deaths in the ED-AKI group occurred within the first 24 hours following 
presentation at the ED (n=25). 24-hour mortality for each AKI stage at ED presentation was 
3.4% in stage one, 6.2% in stage two and 8.5% in stage three, figure 2 (iii).  At 72-hours and 7-
days following ED-AKI hospital admission the proportion of total mortality was 38.4% and 
58.0% respectively. Figure 2 (iv) depicts the distribution of mortality by censoring event day. 
By multivariable COX regression for survival analysis ED-AKI increased the odds of 
mortality (HR, 6.293; 95% CI, 1.887 to 20.790, p=0.003). Similarly, advancing age (yrs) was 
associated with increased odds of mortality (HR, 1.029; 95% CI, 1.012 to 1.047, p=0.001), 
table 4.  
 
Post Discharge Short Term Outcomes 
 Of the total 548 subjects in the ED-AKI cohort, 89 were discharged direct from the ED 
and 459 were admitted to hospital. In total 436 ED-AKI patients were discharged from 
hospital following a diagnosis of ED-AKI.  At 30-days the hospital re-admission rate for the 
discharged ED-AKI group was 20.4% compared to 7.6% in the non-AKI group, p<0.001. 
At 90-days post hospital discharge 43 deaths (10.0%) in the ED-AKI group occurred 
compared to 8 deaths (1.4%) in the non-AKI group (p<0.001). Figure 3 shows the Kaplan-
Meier Survival analysis at 90 days for ED-AKI vs Non-AKI (Figure 3, i) and for AKI stage on 
admission to hospital relative to non-AKI, figure 3 (ii). 
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Post	Discharge	One	Year	Outcomes		 
 At 12-months, 81.7% (n=356) of those with ED-AKI who survived to discharge were 
alive, compared to 95.9% (n=542) of the non-AKI cohort (p<0.001). Of these, 326 (91.6 %) 
patients with ED-AKI and 470 (86.7%) of the non-AKI cohort had sufficient clinical data to 
assess for biochemical evidence of CKD. Mean sCr data was higher in the ED-AKI cohort than 
the non-AKI cohort at 12-months, (106.3 µmol/L versus 80.6 µmol/L, p<0.001), figure 3 (iii). 
Evidence of pre-existing CKD progression occurred in 8.9% (n=29) of the ED-AKI cohort 
compared to 3.4% (n=16) of the non-AKI cohort, (p=0.005), figure 3 (iv). Furthermore, de-
novo CKD was identified in 8.9% (n=29) of the ED-AKI group compared to 2.6% (n=12) of the 
non-AKI group, (p=0.006), figure 3 (v). Of the ten ED-AKI patients who required inpatient RRT 
eight recovered renal function to a level sufficient to negate the need for RRT and two were 
discharged with ongoing RRT. At 12-months three patients in the ED-AKI cohort progressed 
to end-stage renal failure (ESRF) requiring RRT compared to no patients requiring RRT in the 
non-AKI cohort.  
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Discussion 
To the best of our knowledge this is the largest non-administrative epidemiology 
study of adult ED-AKI patients to-date. In this study of 20,421 consecutive adult patients 
attending and undergoing a sCr test in the ED we identified 572 eAlert ED-AKI episodes, 
giving an ED-AKI incidence of 2.8%. The inclusion of all patients attending the ED (both 
admitted and discharged) in the incidence calculation allows a more comprehensive estimate 
of ED-AKI incidence that previous studies which focus solecly on admitted patients would 
over-estimate.  
 Our ED-AKI population was older, more likely to be male and reside in a 
residential/nursing facility on presentation to the ED when compared to a randomly selected 
group of non-AKI ED attendees. Consistent with the finding that AKI occurs in an older 
population our study demonstrated AKI patients are more likely to have multiple co-
morbidities, including pre-existing CKD, cardio-vascular disease, hypertension, dementia, 
malignancy, liver and lung disease. These findings are similar to a smaller epidemiology ED-
AKI study 
(21)
 and mirrors observations in HA- AKI 
(2, 7)
 and ICU-AKI
(10, 11)
 cohorts. 
In those admitted to hospital, the ED-AKI mortality was 24.4% versus 3.2% in the non-
AKI cohort. In the first 24 hours of ED-AKI presentation mortality was 4.6%, which attributed 
to 22.3% of the total ED-AKI mortality. The proportion of the total ED-AKI mortality increased 
to 38.4% and 58% at 72-hrs and 7-days respectively. Patients who progressed to a higher AKI 
stage during their hospital admission had a greater in-hospital mortality, (38.8% versus 21.4% 
in the non-progresses). To our knowledge we are the first group to describe a high acute 
mortality within the early phases of ED-AKI presentation. A small ED-AKI cohort (n=90) 
examined by Scheuermeyer et al 2017, reported the proportion of hospital admissions to be 
65.5%, and a 30-day mortality of 18.6%
(21)
. The higher inpatient mortality of our study may 
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reflect the larger sample size and more comprehensive mechanism of identifying all cases. 
When comparing to other AKI studies in differing clinical settings, in hospital mortality has 
been reported ranging from 20-52%
(1, 6)
. 
ED-AKI patients were more likely to present to acute hospital services in the 
preceding 30-days (18.6% vs 13.3%, p<0.018) and re-attend for acute assessment 30-days 
post discharge (20.4% vs 7.6%, p<0.001). At 90-days 10.1% of ED-AKI discharges died (non-
AKI 1.4%). Acedillo et al, 2017 conducted a large ED-AKI population based administrative 
study in Canada, reporting a 16% readmission and 8% mortality at 30-days
(29)
. In contrast to 
our data on all adults >18yrs of age, this study only examined patients ≥40yrs of age and 
excluded those ED patients who died on arrival or during the ED visit.  
At 12-months those discharged following an ED-AKI episode were more likely to 
develop CKD progression, 8.9% (non-AKI 3.4%) and de-novo CKD, 8.9% (non-AKI 2.6%). The 
association between de-novo CKD and CKD progression has been described in other AKI 
populations
(30-32)
 and confirmed by meta-analysis
(33)
. To our knowledge this is the first study 
of ED-AKI patients examining long term renal outcomes. 
Although our study is of a large well-characterised cohort it has limitations. As a single 
centre study, extrapolation to other health care systems may not be appropriate owing to 
subtle health-care differences. The use of historical biochemistry to infer AKI falls outside the 
strict definition of KDIGO AKI which relies on a sCr rise within 48 hours. Our study aimed to 
limit this impact by reviewing all retrospective and prospective sCr results to validate the e-
alert. Our study did not use urine output to diagnosis AKI, but, in the context of the ED where 
urine outputs are often unavailable the extrapolation of historic sCr data to infer AKI may be 
the most appropriate. Owing to CKD stage 1 and 2 relying upon abnormal urinalysis and/or 
structural pathology for diagnosis, CKD 1 and 2 could not be reliably inferred so our study 
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may underestimate CKD incidence. We were unable to provide data concerning medication 
prescription at the time of ED presentation due to insufficient retrospective data linkage to 
primary care.  I think this is where you can touch eALerts not being able to pick up patients 
with no previous results?  Might then be a way later (if a reviewer pick up) to address the 
reviewers comments – so just a limitation to eAlerts – have a think – not really bothered 
either way to be honest!! 
In conclusion, we present the largest non-administrative epidemiology study of ED-
AKI patients to date. ED-AKI is an independent risk for death particularly in the early stages of 
admission. ED-AKI patients more often access acute medical services before the incident 
event and after recovery and discharge to the community. Following discharge ED-AKI is 
associated with a heightened mortality and adverse long term renal outcomes. How access to 
healthcare, patient education and enhanced follow-up will impact ED-AKI acutely and 
chronically is unknown but further studies are required.  
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Figure 1: Inclusion and Exclusion criteria used to define the ED-AKI and the non-AKI 
cohorts  
  
 
 
 23 
 
Table 1: Demographic Data: Emergency Department AKI versus Non-AKI  
Variable ED-AKI 
(n=548) 
Non-AKI 
(n=571) 
P value 
Age (yr), mean ±  SD 70.3 ± 18.0 54.7 ± 21.8 <0.001 
Men, % (n) 54.9 (301) 46.2 (264) 0.004 
Nursing/Residential Home Resident, % (n) 19.5 (107) 6.5 (37) <0.001 
Mean Creatinine (pre-admission) ±  SD 
(µmol/L) 
94.5 ± 42.7 77.0 ± 26.8 <0.001 
Baseline eGFR (pre-admission), mean ±  SD  81.0  ±  31.0 101.7 ±  29.0 <0.001 
Pre-admission CKD 3a-5, % (n) 
 
Stage 3A 
Stage 3B 
Stage 4 
Stage 5 
 
27.6 (151) 
 
15.9 (87) 
8.8 (48) 
2.5 (14) 
0.4 (2) 
7.9 (45) 
 
4.7 (27) 
2.1 (12) 
0.9 (5) 
0.2 (1) 
<0.001 
Comorbid conditions, % (n) 
†, ‡
 
Peripheral Vascular Disease 
Cardio Vascular Disease 
Hypertension 
Diabetes 
Hyperlipidaemia 
Connective Tissue disease/vasculitis 
Lung Disease 
Liver Disease 
Dementia 
Active Malignancy 
 
5.3 (29) 
35.8 (196) 
52.6 (288) 
28.1 (154) 
32.7 (179) 
5.1 (28) 
16.6 (91) 
5.3 (29) 
10.8 (59) 
15.5 (85) 
 
1.4 (8) 
22.8 (130) 
30.1 (172) 
10.2 (58) 
17.7 (101) 
2.6 (15) 
6.8 (39) 
0.9 (5) 
4.0 (23) 
6.8 (39) 
 
0.003 
<0.001 
<0.001 
<0.001 
<0.001 
0.420 
<0.001 
<0.001 
<0.001 
<0.001 
 
† 
Peripheral Vascular Disease defined as symptomatic claudication and documented clinical/radiological 
evidence of vascular disease and/or received non-coronary angioplasty, vascular graft or amputation. Cardio 
Vascular Disease defined as known Angina, Myocardial Infarction, Heart Failure, Stroke or Transient 
Ischaemic Attack. Hypertension defined as present if requiring medical treatment. Diabetes included both 
type 1 or type 2 diabetes. Hyperlipidaemia defined as those requiring lipid modifying agents. Connective 
Tissue disease/Vasculitis defined as known Vasculitis, Rheumatoid Arthritis, Systemic Lupus Erythematosus, 
Systemic Sclerosis or Polymyositis. Lung disease defined as confirmed COPD, Intestinal Lung Disease or 
Pulmonary Hypertension. Liver disease includes those with known Cirrhosis. Dementia defined as diagnosed 
dementia of any aetiology. Active malignancy includes those with palliative malignancy, undergoing active 
treatment or surveillance.  
‡ 
P-values were adjusted for multiple tests through Bonferroni adjustment; multiplication of unadjusted p-
value by number of tests (n=10) 
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Table 2: Patient Contact Data: Emergency Department AKI versus Non-AKI 
Variable ED-AKI (n=548) Non-AKI (n=571) P value 
Previous hospital admission, % (n)
 †
 18.6 (102) 13.3 (76) 0.018 
Laboratory Indexes on admission, 
mean ±SD (n) 
Creatinine (umol/L) 
Sodium (mmol/L) 
Albumin (g/L) 
Alanine transaminase (U/L) 
Bilirubin (umol/L) 
C-Reactive Protein (mg/L) 
White Blood Cell (10
9
/L) 
 
 
 
190.5 ±117.6 (548) 
135.3 ±6.6 (548) 
31.1 ±6.7 (511) 
58.2 ±161.0 (499) 
22.0 ±43.5 (499) 
107.3 ±114.9 (480) 
12.8 ±7.2 (544) 
 
 
 
78.09 ±27.9 (571) 
137.6 ±4.0 (571) 
36.1 ±6.0 (499) 
34.9 ±90.9 (486) 
12.6 ±19.0 (487) 
29.9 ±54.9 (411) 
9.7 ±4.6 (559) 
 
 
 
<0.001 
<0.001 
<0.001 
0.005 
<0.001 
<0.001 
<0.001 
 
AKI stage at ED contact, % (n) 
No-AKI 
Stage 1 AKI 
Stage 2 AKI  
Stage 3 AKI  
  
 
/ 
68.8 (377) 
20.4 (112) 
10.8 (59) 
 
100 (571) 
/ 
/ 
/ 
 
 
Hospital Admission, % (n)
‡
 83.8 (459) 32.9 (188) <0.001 
Discharge Diagnosis, % (n)
 §
 
Sepsis 
Trauma 
Surgical Emergency 
Cardiovascular 
Gastrointestinal medical 
Urological obstruction 
Malignancy 
Diabetes 
Medical/Surgical general 
Unknown 
 
34.1 (187) 
4.7 (26) 
6.9 (38) 
10.8 (59) 
13.1 (72) 
10.4 (57) 
2.6 (14) 
5.5 (30) 
4.6 (25) 
7.3 (40) 
 
13.5 (77) 
11.4 (65) 
3.7 (21) 
9.8 (56) 
6.3 (36) 
1.2 (7) 
1.9(11) 
0.2 (1) 
48.5 (277) 
3.5 (20) 
 
<0.001 
<0.001 
0.290 
1.00 
0.002 
<0.001 
1.00 
<0.001 
<0.001 
0.10 
Sepsis defined as clinical reporting in discharge summaries. Trauma was defined as musculoskeletal injury 
requiring medical intervention or observation. Surgical emergency was defined as ruptured abdominal 
viscera, abdominal catastrophe or any emergency surgical intervention. Cardiovascular defined as acute 
coronary syndrome, angina or cerebrovascular event. Gastrointestinal medical defined as disturbance in gut 
activity requiring medical support. Urological obstruction defined as bladder outflow obstruction or 
hydronephrosis as primary cause for admission. Diabetes defined as diabetic complication requiring medical 
intervention. Medical/Surgical general defined as non-sepsis related infections, surgical pathology not 
requiring an acute operation.   
†
 Previous hospital admission defined as any unscheduled admission to hospital within 30-days prior to 
incident event. 
‡
 Hospital admission defined as the sum of those who died ≤ 24hrs following admission and 
those who were admitted for >24 hrs. 
§ 
Discharge diagnosis was collated following review of all discharge 
summaries. Chi-squared test was performed and p-values were adjusted for multiple tests through Bonferroni 
adjustment; multiplication of unadjusted p-value by number of tests (n=10). 
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Table 3: In hospital Outcomes for those admitted to hospital    
Variable ED-AKI  
(n=459) 
Non-AKI  
(n=188) 
P value 
Median length of hospital admission (IQR) (d) 7.0 (3-16) 6.0 (3-13.75) 0.246 
ICU admission % (n) 9.8 (45) /  
Median length of ICU admission (IQR) (d) 5.0 (3-14) /  
AKI event during admission, % (n) 100.0 (459) 10.6 (20) <0.001 
Peak AKI stage during admission, % (n) 
No-AKI 
Stage 1 AKI 
Stage 2 AKI  
Stage 3 AKI 
 
 
/ 
54.5 (250) 
25.7 (118) 
19.8 (91) 
 
89.4 (168) 
8.0 (15) 
2.1 (4) 
0.5 (1) 
 
In-hospital mortality, % (n) 24.4 (112) 3.2 (6) <0.001 
Mortality in ICU, % (n)
b
 31.1 (14) / / 
Mortality relative to Peak AKI stage during 
admission, % (n) 
No-AKI 
Stage 1 AKI 
Stage 2 AKI 
Stage 3 AKI 
 
 
/ 
17.2 (43) 
27.1 (32) 
40.7 (37) 
 
 
3.0 (5) 
6.7 (1) 
/ 
/ 
 
Hospital admission defined as the sum of those who died ≤ 24hrs following admission and those who were 
admitted for >24 hrs. Peak AKI stage defined using the highest sCr result recorded during admission which 
was then staged according to KDIGO AKI criteria. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 26 
Figure 2: The Patient Journey 
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≤24 hrs, 22.3% (n= 25)
≤72 hrs, 38.4% (n= 43)
≤7 days, 58.0% (n= 65) 
Total mortality of all hospital admissions n= 112  
Proportion Of 
Total Mortality  
 
In total 118 patients died in both cohorts, ED-AKI (n=112) and non-AKI (n=6). The patient journey from 
admission to discharge is described in image (i). The proportion of the total mortality for the ED-AKI cohort 
occurring in the first 24 hours of admission was 22.3% (n=25), image (iii). Of these the greatest proportion of 
deaths occurred in the group with stage-3 AKI on admission (n=5, 8.5%), image (iii). Progression of the initial 
presenting ED-AKI stage to a higher AKI stage occurred in 80 patients of which inpatient mortality was 38.8% 
(n=31). This compared to 379 patients who did not progresses to a higher AKI stage of which 21.4% (n=81) 
died during admission. The mortality relative to AKI progression is shown image (ii). 
 27 
 
Table 4: Univariate and multivariate Cox regression analysis of prognostic factors for in hospital survival  
Variable Univariate Analysis Multivariate Analysis 
HR 95% CI p-value HR 95% CI p-value 
ED-AKI versus non-AKI 7.073 3.109-16.091 <0.001* 6.293 1.887-20.790 0.003* 
Age, yrs 1.032 1.018-1.045 <0.001* 1.029 1.012-1.047 0.001* 
NH/RH Resident  1.628 1.088-2.436 0.018* 1.182 0.717-1.946 0.512 
Albumin  0.927 0.901-0.954 <0.001* 0.946 0.907-0.986 0.008* 
ALT 1.001 1.000-1.002 0.006* 1.001 1.000-1.001 0.218 
C-Reactive Protein 1.002 1.000-1.003 0.009* 1.000 0.998-1.002 0.938 
White Blood Cell count 1.038 1.017-1.059 <0.001* 1.016 0.990-1.043 0.223 
CKD evidence 1.6112 1.105-2.352 0.013* 1.089 0.668-1.776 0.733 
CT disease/vasculitis  2.651 1.456-4.826 0.001* 1.120 0.514-2.441 0.776 
Length of Stay, days 0.808 0.764-0.855 <0.001* 0.004 0.000-0.083 <0.001* 
Dementia 1.101 0.692-1.752 0.684    
Malignancy 1.530 0.970-2.414 0.067    
ICU admission 1.257 0.717-2.204 0.452    
Male vs. female 0.967 0.674-1.388 0.857    
Sodium 1.026 0.999-1.054 0.061    
Bilirubin  1.002 0.999-1.005 0.252    
Peripheral Vascular Disease 1.021 0.497-2.100 0.954    
Cardiovascular Disease 0.856 0.589-1.243 0.413    
Hypertension 0.889 0.618-1.277 0.524    
Diabetes 0.834 0.539-1.290 0.415    
Hyperlipidaemia  0.660 0.436-1.001 0.051    
Lung Disease 0.684 0.571-1.445 0.684    
Liver Disease 1.457 0.779-2.726 0.239    
Cox regression for survival analysis was used to investigate the association between survival time of those 
admitted to hospital and predictor variables. The influence of demographic, biochemical, haematological, co-
morbid conditions, ICU admission and length of hospital stay was used to inform variables which convey 
risk/protection. Analysis datasets included only those who were defined as being admitted to hospital. The 
listed variables were initially investigated by univariate analysis to inform those of statistical significance 
which were then used in the model of multivariable analysis. P<0.05 was donated as statistically significant 
and are bolded and stared to facilitate easy of reference. Hazard Ratio (HR) <1 corresponds to a reduction in 
hazard and >1 an increase in hazard.  
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Figure 3: Short and Long-Term Outcomes  
(i)                                                             (ii) 
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Kaplan-Meier survival Analysis for all-cause mortality at 90-days post discharge for ED-AKI versus non-AKI is 
shown in image (i). The survival distributions for ED-AKI versus non-AKI were statistically different !2 2   = 
44.629, p<0.001. Analysis of AKI stage on admission was also completed, image (ii). The survival distributions 
by AKI stage on admission were statistically significant !2 2   = 56.386, p<0.001.  
At 12-months 326 patients of the ED-AKI and 470 of the non-AKI cohort had sufficient clinical data to infer 
new baseline sCr. Image (iii) depicts the mean serum creatinine of patients 12-months following discharge, data 
is displayed as mean (±SD). The incidents of CKD progression at 12 months is displayed in image (iv). CKD 
progression is defined as pre-ED attendance baseline CKD 3A-4 progressing to a higher CKD stage and/or 
eGFR at baseline (in only those with CKD 3A-5) or a reduction in eGFR by ≥5ml/min over 12 months. Data is 
displayed as percentage (n).  The proportion of patients developing De-Novo CKD at 12-months post discharge 
is presented in image (v). De-Novo CKD is defined as a new diagnosis of CKD 3A-5 12-months post hospital 
discharge. Data is displayed as percentage (n).   
 
 
 
 
 
 
 
 
 
 
